Medtronic Puts Its 2014 Tyrx Buy To The Test With Large Study
This article was originally published in The Gray Sheet
Executive Summary
The 7,000-patient WRAP-IT study will measure the clinical and cost benefits of employing the Tyrx antibacterial envelope, acquired by Medtronic last year, to reduce infections following cardiac rhythm management device implant procedures. Medtronic hopes to leverage new incentives for hospitals to cut infection rates.
You may also be interested in...
Medtronic Takes Aim At Implantable Device Infections with TYRX Buy
The $160 million cash acquisition fits with the firm’s efforts to fashion itself into a health care services and solutions company, rather than pure device firm. TYRX makes anti-bacterial envelopes for implanted devices, and has FDA clearances with cardiac implantable electronic devices and spinal cord neurostimulators.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.